Results 121 to 130 of about 24,516 (282)

Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis

Leukemia Research Reports, 2015
Pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) is associated with increased maternal and fetal morbidity and mortality. There is limited published experience regarding therapy of PNH during pregnancy.
Ruby Sharma, Alla Keyzner, Johnson Liu, Thomas Bradley, Steven L. Allen   +4 more
doaj   +1 more source

Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis

Therapeutic Advances in Neurological Disorders, 2020
Background: Eculizumab is a humanized monoclonal antibody that targets complement protein C5 and inhibits terminal complement-mediated damage at the neuromuscular junction.
Munenori Oyama, Kensuke Okada, Masayuki Masuda, Yuko Shimizu, Kazumasa Yokoyama, Akiyuki Uzawa, Naoki Kawaguchi, Ryotaro Ikeguchi, Yasunobu Hoshino, Taku Hatano, Yukiko Ozawa, Jin Nakahara, Hitoshi Aizawa, Kazuo Kitagawa, Nobutaka Hattori, Satoshi Kuwabara, Hiroyuki Murai, Shigeaki Suzuki   +17 more
doaj   +1 more source

Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations [PDF]

, 2013
Hemolytic uremic syndrome (HUS) is a disease of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. About 90% of cases are secondary to infections by Escherichia coli strains producing Shiga-like toxins (STEC-HUS), while 10% are ...
Alberti, M., Bresin, E., Galbusera, M., Noris, M., Piras, R., Remuzzi, G., Thaiss, F., TRIPODO, Claudio, Valoti, E.   +8 more
core   +1 more source

Application of a policy framework for the public funding of drugs for rare diseases [PDF]

, 2014
BACKGROUND: In many countries, decisions about the public funding of drugs are preferentially based on the results of randomized trials. For truly rare diseases, such trials are not typically available, and approaches by public payers are highly variable.
Christine Seager, D Coyle, Doug Coyle, E Winquist, Eric Winquist, Gerald A. Evans, Janet Martin, Joe T. R. Clarke, N Daniels, R Cookson, Winnie Chan   +10 more
core   +1 more source

Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern

Case Reports in Nephrology, 2016
In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements.
Camino García Monteavaro, Carmen Peralta Roselló, Borja Quiroga, José María Baltar Martín, Lorena Castillo Eraso, Fernando de Álvaro Moreno, Alberto Martínez Vea, María Teresa Visus-Fernández de Manzanos   +7 more
doaj   +1 more source

Erythropoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria

Haematologica, 2007
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by intravascular hemolysis leading to anemia and other clinical manifestations. Transfusions are often required to support hemoglobin at tolerable levels.
A. Hill, S.J. Richards, R.P. Rother, P. Hillmen   +3 more
doaj   +1 more source

Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. [PDF]

, 2014
Neuromyelitis optica (NMO) is an autoimmune disease of the CNS that is characterized by inflammatory demyelinating lesions in the spinal cord and optic nerve, potentially leading to paralysis and blindness.
A Bar-Or, A Davies, A Iyer, A Jacob, A Jacob, A Jacob, A Jacob, A McKeon, A Nagaishi, A Rossi, A Uzawa, A Warth, AE Damiano, Alan S. Verkman, AMC Faria, B Banwell, B Bielekova, B Bourre, B Weinstock-Guttman, BA Cree, BC Kieseier, BG Weinshenker, BL Raveendra, BM Greenberg, BM Greenberg, C Costanzi, C Trebst, C Wrzos, CF Lucchinetti, CH Polman, D Ricklin, D Ricklin, D Yuksel, DB Bichuetti, DB Bichuetti, DG Brum, DJ Kimbrough, DK Sato, DM Wingerchuk, DM Wingerchuk, E Gomori, EW Gelfand, F Shimizu, G Pentón-Rol, GG Illei, GS Bedi, H Kita, H Merle, H Wang, H Wen, H Yaguchi, H Zephir, H Zhang, H Zhang, HH Wang, HL Pellkofer, HL Pellkofer, HL Pellkofer, HM Reeves, I Ayzenberg, I Kleiter, I Kleiter, I Nakashima, J Bakker, J Fagius, J Kitley, J Kitley, J Kitley, J Kitley, J Kitley, J Kitley, J Palace, J Ratelade, J Ratelade, J Ratelade, J Ratelade, J Shimizu, JA Cabrera-Gomez, Jeffrey L. Bennett, JH Min, JL Bennett, JM Crane, JM Tillema, JR Faulkner, JS Wu, K Iwata, K Kawabata, K Miyamoto, K Okada, K Rostasy, K Sugita, KR Carson, L Elsone, L Tradtrantip, L Tradtrantip, L Tradtrantip, L Tradtrantip, LA Lewis, M Araki, M Barnett, M Bonnan, M Bonnan, M Botto, M Bradl, M Collin, M De Falco, M Keegan, M Koga, M Matiello, M Matiello, M Pohl, M Reindl, M Ringelstein, M Varrin-Doyer, MA Mealy, MA Sahraian, Marios C. Papadopoulos, MC Papadopoulos, MJ Magraner, N Asavapanumas, N Asavapanumas, N Asgari, N Chihara, N Chihara, N Muls, O Hammer, P Cabre, P Huppke, P Imbach, PF Zipfel, PJ Barnes, PW Phuan, PW Phuan, PW Phuan, R Deschamps, R Reuss, RC Axtell, RE Young, RR Voskuhl, S Izaki, S Jacob, S Jarius, S Jarius, S Jarius, S Jarius, S Jarius, S Jarius, S Jarius, S Kim, S Mader, S Mihai, S Saadoun, S Saadoun, S Saadoun, S Saadoun, S Saadoun, S Saadoun, S Watanabe, S-H Kim, S-H Kim, S-H Kim, S-H Kim, SH Kim, SJ Pittock, SR Hinson, SR Hinson, SR Hinson, SR Kalluri, T Hosokawa, T Kageyama, T Matsuoka, T Matsushita, T Vincent, TE Lotze, TF Tedder, UC Linhares, V Papayannopoulos, VA Lennon, VA Lennon, VT Chu, W Kim, Y Li, Y Warabi, YD Fragoso   +183 more
core   +1 more source

Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome? [PDF]

, 2017
Eva Rodríguez, Clara Barrios, María José Soler   +2 more
openalex   +1 more source

A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy [PDF]

, 2020
R. D. Wright, Fariba Bannerman, Michael W. Beresford, Louise Oni   +3 more
openalex   +1 more source

Safety and Effectiveness of Eculizumab throughout Three Pregnancies in a Patient with Refractory Generalized Myasthenia Gravis: A Case Report

Case Reports in Neurology
We describe maternal and fetal outcomes in a patient who had three successful pregnancies while being treated with eculizumab for AChR+ gMG.
Nadia Khalil, Claudia Guerra Hernandez, Jerrica Farias, Kathleen Murray, Niraja Suresh, Clifton Gooch, Tuan H. Vu   +6 more
doaj   +1 more source